Lipoprotein metabolism in diabetes

Current Opinion in Lipidology

Volumn 5, Issue 3, 1994, Pages 216-220

  Howard, Barbara V ^a  

^a Medlantic Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; CHLOROQUINE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RETINOL PALMITATE; SIALIC ACID; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET; EXERCISE; GLUCAGON BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 0028365764     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199405030-00009     Document Type: Review

References (38)

1. Howard BV Lipoprotein Metabolism in Diabetes Mellitus. J Lipid Res 1987, 28:613-628.
2. Lewis GF, O'Meara NM, Solyts PA, Blackman JD, Iverius PH, Pugh WL, Getz GS, Polonsky KS: Fasting Hypertriglyceridemia in Non-Insulin-Dependent Diabetes Mellitus is an Important Predictor of Postprandial Lipid and Lipoprotein Abnormalities. J Clin Endocrin Metab 1991, 72.934-944.
3. Ida Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM: Differences in Postprandial Lipemia Between Patients with Normal Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus. J Clin Endocrin Metab 1993, 76:172-177. Postprandial increases in triglyceride-rich lipoproteins were compared in 10 patients with NIDDM, and 10 nondiabetic controls matched for age, sex, body mass index and plasma triglycerides. Postprandial retinyl palmitate concentrations were higher in patients with NIDDM and correlated inversely with HDL.
4. McKeigue PM, Laws A, Chen YD, Marmot MG, Reaven GM: Relation of Plasma Triglyceride and ApoB Levels to Insulin-Mediated Suppression of Non-Esterified Fatty Acids. Arterioscler Thromb 1993, 13:1187-1192.
5. Frayn KN, Coppack SW, Humphreys SM, Clark ML, Evans RD: Periprandial Regulation of Lipid Metabolism in Insulin-Treated Diabetes Mellitus. Metabolism 1993, 42:504-510
6. Jeng CY, Sheu HH, Jaspan JB, Polonsky KS, Chen YDI, Reaven GM: Glucagon Does Not Increase Plasma Free Fatty Acid and Glycerol Concentrations in Patients with Non-Insulin-Dependent Diabetes Mellitus. J Clin Endocrin Metab 1993, 77.6-10. An increase in the plasma glucagon level comparable with that seen in patients with NIDDM was associated with lower, not higher, plasma free fatty acid and glycerol concentrations in patients with NIDDM, thus eliminating the possibility that elevations in plasma glucagon are responsible for the higher plasma free fatty acid seen in NIDDM patients.
7. Harris MI: Hypercholesterolemia in Individuals with Diabetes and Glucose Intolerance in the US Population. Diabetes Care 1991, 14:366-374.
8. Cowie CC, Howard BV, Harns MI: Plasma Lipoproteins in Blacks and Whites with Non-Insulin-Dependent Diabetes in the US Population Circulation 1994, in press. This article presents lipoprotein data on a population-based sample of Blacks and Whites from the National Health and Nutrition Survey II. In both races, diabetes was associated with higher triglycerides and lower HDL. LDL concentrations compared with nondiabetics were higher in Whites with NIDDM. but lower in Blacks with NIDDM, suggesting that there may be racial differences in the effect of diabetes on plasma lipoproteins.
9. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem 1972, 18:499-502.
10. Rubies-Prat J, Reverter JL, Senti M, Pedre-Botet J, Salinas I, Lucas A, Nogues X, Sanmarti A: Calculated Low-Density Lipoprotein Cholesterol Should Not be Used or Management of Lipoprotein Abnormalities in Patients With Diabetes Mellitus. Diabetes Care 1993, 16:1081-1086. Comparison of LDL cholesterol, calculated by the Friedewald formula and measured LDL cholesterol, showed greater concordance in control subjects than in subjects with NIDDM, suggesting that the Friedewald formula may result in a less accurate assessment of LDL cholesterol in patients with NIDDM.
11. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM: LDL Subclass Phenotypes and Triglyceride Metabolism in Non-Insulin-Dependent Diabetes. Arterioscler Thromb 1992, 12:1496-1502. LDL size and subclass phenotype were compared in men with NIDDM and compared with controls. Average LDL size was lower and the per cent of subclass pattern B was higher in the NIDDM group.
12. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV: Greater Effect of Diabetes on LDL Size in Women Than in Men. Diabetes Care 1994, in press. LDL size and subclass distribution were evaluated in Mexican Americans and non-Hispanic Whites in the San Antonio Heart Study. In both ethnic groups, diabetes was associated with lower mean LDL size and a greater proportion of LDL subclass B. The differences between diabetics and nondiabetics were greater in women.
13. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic Lipoprotein Phenotype: A Proposed Genetic Marker for Coronary Heart Disease Risk. Circulation 1990, 82:495-506.
14. Detwart MW, Laker MF, Dyer RG, Game F, Mitcheson J, Winocour PH, Alberti KGMM: Lipoprotein Compositional Abnormalities and Insulin Resistance in Type II Diabetic Patients with Mild Hyperlipidemia. Arterioscler Thromb 1993, 13:1046-1052. This presents a thorough analysis of LDL composition in NIDDM patients. Compared with nondiabetic control subjects matched for age, body mass index, total triglyceride, and total cholesterol, LDL in the diabetic subjects had a higher ratio of apoB to total lipids, a higher hydrated density, and smaller average size.
15. Haaber AB, Deckert M, Slender S, Jensen T. Increased Urinary Loss of High Density Lipoproteins in Albuminurie Insulin-Dependent Diabetic Patients. Scand J Clin Lab Invest 1993, 53:191-196.
16. Ahnadi CE, Masmoudi T, Berthezene F, Ponsin G: Decreased Ability of High Density Lipoproteins to Transfer Cholesterol Esters in Non-Insulin-Dependent Diabetes Mellitus. Euro J Clin Invest 1993, 23:459-465. The rate of the transfer of esterified cholesterol from HDL to VLDL and LDL was evaluated in an in-vitro assay designed to measure the unidirectional transfer from HDL. HDL from NIDDM subjects had a decreased ability to act as a donor of esterified cholesterol, which was related to their higher triglyceride content and lower ratio of free cholesterol to phospholipids.
17. Salzer B, Stavljenic A, Jurgens G, Dumic M, Radica A: Polymorphism of Apolipoprotein E, Lipoprotein (a), and Other Lipoproteins in Children with Type I Diabetes. Clin Chem 1993, 39:1427-1432. Lp(a) and apoE phenotype were measured in 450 type I diabetic children, 13-14 years of age. Compared with healthy school children matched for age and gender, concentrations of Lp(a) were significantly higher in the diabetic children.
18. Couper JJ, Bates DJ, Cocciolone R, Mafarey AM, Boulton TJ, Penfold JL, Ryall RG. Association of Lipoprotein (a) With Puberty in IDDM. Diabetes Care 1993, 16:869-873
19. Kapelrud H, Bangstad HJ, Darl-Jorgensen K, Hanssen KF: Serum Lp(a) Lipoprotein Concentrations in Insulin-Dependent Diabetic Patients with Microalbuminuria. Br Med J 1991, 303:675-678.
20. Maser RE, Usher D, Becker DJ, Drash AL, Kuller LH, Orchard TJ: Lipoprotein(a) Concentration Shows Little Relationship to IDDM Complications in the Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes Care 1993, 16:755-758. Lp(a) concentrations were measured in 186 individuals with IDDM participating in a 10-year prospective study. No relationship was seen between Lp(a) concentrations and either macrovascular or microvascular complications.
21. Howard BV, Howard WJ. Dyslipidemia in Non-Insulin Diabetes Mellitus. Endocrin Rev 1994, in press.
22. Velho G, Erlich D, Turpin E, Neel D, Cohen D, Froguel P, Passa P: Lipoprotein(a) in Diabetic Patients and Normoglycemic Relatives in Familial NIDDM. Diabetes Care 1993, 16:742-747. Lp(a) concentrations were compared in 577 NIDDM patients and 260 normoglycemic relatives. There was no difference in Lp(a) concentrations between the diabetic and the nondiabetic groups. However, diabetic patients with previous myocardial infarction had significantly higher levels of Lp(a) than the patients without a history of coronary heart disease.
23. Heller FR, Jamart J, Honore P, Derue G, Novik V, Galanti L, Parfonry A, Hondekujn JC, Buysschaert M: Serum Lipoprotein (a) in Patients with Diabetes Mellitus. Diabetes Care 1993, 16:819-823.
24. Sobenin IA, Tertov W, Koschinsky T, Bunting CE, Slavina ES, Dedov II, Orekhov AN: Modified Low-Density Lipoprotein from Diabetic Patients Causes Cholesterol Accumulation in Human Intimal Aortic Cells. Atherosclerosis 1993, 100:41-54. Serum samples from 99 IDDM and 81 NIDDM patients induced increased total cholesterol content of cultured aortic intimal cells. The cholesterol-accumulating effect was related to the low-density lipoprotein fraction and correlated with the degree of glycation and desialylation.
25. Ukkola O, Kervinen K, Salmela I, von Dickhoff K, Laakso M, Kesaniemi YA: Apolipoprotein E Phenotype is Related to Macro- and Microangiopathy in Patients with Non-Insulin-Dependent Diabetes Mellitus. Atherosclerosis 1993, 101:9-15.
26. Detection and Management of lipid Disorders in Diabetes. Diabetes Care 1993, 16:106-112. This is a report of the consensus development conference on detection and the management of lipid disorders in diabetes. It reviews the epidemiology of lipid disorders in diabetes and the relationship to cardiovascular disease. Goals for therapy are presented and further research needs are discussed.
27. Akanji AO, Osifo E, Kirk M, Hockaday DRL The Effects of Changes in Plasma Non-Esterfied Fatty Acid Levels on Oxidative Metabolism During Moderate Exercise in Patients with Non-Insulin-Dependent Diabetes Mellitus. Metabolism 1993, 42:426-434. This examines intermediary metabolism and indirect calonmeuy in 10 NIDDM patients before, during, and after moderate exercise. It demonstrates the validity of the glucose/fatty acid cycle during exercise in NIDDM, and supports the contention that exercise may be of likely benefit to the diabetic patient.
28. Murakami K, Shimizu M, Yamada N, Ishibashi S, Shimano H, Yazaki Y, Akanuma Y: Apolipoprotein E Polymorphism is Associated with Plasma Cholesterol Response in a 7-Day Hospitalization Study for Metabolic and Dietary Control in NIDDM. Diabetes Care 1993, 16:564-369.
29. Savolainen MJ, Rantala M, Kervinen K, Jarvi L, Suvanto K, Rantala T, Kesaniemi YA: Magnitude of Dietary Effects on Plasma Cholesterol Concentration: Role of Sex and Apolipoprotein in E Phenotype. Atherosclerosis 1991, 86:145-152.
30. Vessby B: Dietary Supplementation with N-3 Polyunsaturated Fatty Acids in Type 2 Diabetes: Effects on Glucose Homeostasis. Am NY Acad Sci 1993, 683:244-249.
31. Kasim S: Dietary Marine Fish Oils and Insulin Action in Type 2 Diabetes. Am NY Acad Sci 1993, 683-250-257.
32. Connor WE, Prince MJ, Ullmann D, Riddle M, Hatcher L, Smith FE, Wilson D: The Hypotriglyceridemic Effect of Fish Oil in Adult-Onset Diabetes Without Adverse Glucose Control. Ann N Y Acad Sci 1993, 683:337-340. Results of a 6-month randomized, placebo-controlled, crossover trial of N-3 fatty acid therapy in 16 individuals with NIDDM and hypertriglyceridemia. Significant triglyceride lowering was achieved with no adverse effect on glucose control. LDL-cholesterol levels, however, increased on N-3 fatty acid therapy.
33. Westerveld HT, de Graaf JC, van Breugel HHFI, Akkerman JWN, Sixma JJ, Erkelens DW, Banga JD: Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein (a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM. Diabetes Care 1993, 16:683-688. This double-blind randomized control study of 24 NIDDM subjects investigated EPA administration for 8 weeks. Platelet aggregation was reduced, triglycerides tended to be reduced, and glycemic control was not influenced. LDL cholesterol, however, was elevated after EPA administration.
34. Nagi DK, Yudkin JS: Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in IIDDM Subjects. Diabetes Care 1993, 16:621-629. Metformin was compared with placebo in 27 NIDDM subjects for 12-week treatment periods. Metformin was associated with lower plasma glucose, lower triglycerides, total and LDL cholesterol, and lower plasminogen activator inhibitor-1. Insulin resistance, as measured with an euglycemic clamp, was also improved.
35. The Diabetes Control and Complications Trial Research Group: Lipid and Lipoprotein Levels in Patients with IDDM: Diabetes Control and Complications Trial Experience. Diabetes Care 1992, 15:886-694.
36. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR: Effects of Gemfibrozil on Low-Density Lipoprotein Particle Size, Density Distribution, and Composition in Patients with Type II Diabetes. Diabetes Care 1993, 16:584-592. Gemfibrozil was compared with placebo in 60 NIDDM patients in a double-blind study. Mean LDL density decreased and the mean particle diameter increased during gemfibrozil therapy. Changes in LDL composition correlated with decreases in plasma triglyceride.
37. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, Froesch ER: Improvement of Lipid Profile in Type 2 (Non-Insulin-Dependent) Diabetes Mellitus by Insulin-like Growth Factor I. Diabetologia 1993, 36:465-469.
38. Powrie JK, Shojaee-Moradie F, Watts GF, Smith GD, Sonksen PH, Jines RH: Effects of Choloroquine on the Dyslipidemia of Non-Insulin-Dependent Diabetes Mellitus. Metabolism 1993, 42:415-419.